Predictive Oncology Inc.
POAI
$0.95
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -95.99% | 2,151.02% | 91.36% | -48.91% | -86.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.99% | 2,151.02% | 91.36% | -48.91% | -86.27% |
| Cost of Revenue | 30.94% | 101.34% | 20.18% | 101.12% | -91.30% |
| Gross Profit | -129.03% | 470.45% | 312.60% | -74.29% | -83.83% |
| SG&A Expenses | 5.01% | -34.01% | -21.15% | -25.77% | -38.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.16% | -33.16% | -18.16% | -22.13% | -40.93% |
| Operating Income | -7.92% | 36.15% | 29.74% | 15.52% | 35.08% |
| Income Before Tax | 19.45% | 35.88% | 29.79% | 16.92% | 37.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.45% | 35.88% | 29.79% | 16.92% | 37.38% |
| Earnings from Discontinued Operations | 87.36% | 75.94% | 85.78% | -95.45% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.92% | 42.09% | 37.57% | 2.17% | 18.91% |
| EBIT | -7.92% | 36.15% | 29.74% | 15.52% | 35.08% |
| EBITDA | -8.06% | 36.46% | 30.19% | 11.75% | 32.76% |
| EPS Basic | 66.67% | 67.10% | 62.01% | 38.35% | 30.53% |
| Normalized Basic EPS | 58.75% | 63.58% | 58.13% | 46.46% | 44.02% |
| EPS Diluted | 66.42% | 67.15% | 62.01% | 38.35% | 30.19% |
| Normalized Diluted EPS | 58.75% | 63.58% | 58.13% | 46.46% | 44.02% |
| Average Basic Shares Outstanding | 95.27% | 76.04% | 64.32% | 58.66% | 16.72% |
| Average Diluted Shares Outstanding | 95.27% | 76.04% | 64.32% | 58.66% | 16.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |